Risto-cel, a gene-edited cell therapy formerly called BEAM-101, for severe SCD, benefits patients for nearly two years, new ...

A lack of accessibility in a non-inclusive society for those with a disability comes at a terrible cost, writes columnist.

Casgevy safely and effectively prevents vaso-occlusive crises in children ages 5 to 11 with severe sickle cell disease, trial ...